Quick Answer
Serina Therapeutics, Inc. reported Gross Profit of $102.0 thousand for fiscal year 2023.
Serina Therapeutics, Inc. Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2023 | $102.0K | +385.7% |
| 2022 | $21.0K | -83.2% |
| 2021 | $125.0K | -62.7% |
| 2020 | $335.0K | -77.4% |
| 2019 | $1.48M | +43.8% |
| 2018 | $1.03M | -16.5% |
| 2017 | $1.24M | — |
Quarterly Gross Profit
| Quarter Ending | Gross Profit | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $34.0K | +750.0% | +750.0% |
| June 30, 2023 | $4.0K | -33.3% | -55.6% |
| March 31, 2023 | $9.0K | +125.0% | +125.0% |
| September 30, 2022 | $4.0K | -81.8% | -33.3% |
| June 30, 2022 | $6.0K | -75.0% | +50.0% |
| March 31, 2022 | $4.0K | -92.5% | -81.8% |
| September 30, 2021 | $22.0K | -57.7% | -8.3% |
| June 30, 2021 | $24.0K | -42.9% | -54.7% |
- Serina Therapeutics, Inc. showed an increase of +385.7% in Gross Profit compared to the prior fiscal year.
- Over the 2017–2023 period, Serina Therapeutics, Inc.’s gross profit has declined by 91.7% (from $1.24 million to $102.0 thousand).
- The most recent figure is from Serina Therapeutics, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 22, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: